Plasmid DNA and viral vector-based vaccines for the treatment of cancer.
Plasmid DNA and viral vector-based cancer vaccines have many inherent features that make them promising cancer vaccine candidates. This review focuses on the use of plasmid DNA and viral vector vaccines to deliver tumour-specific antigens to induce a tumour-specific immune response. Examples of different antigen delivery systems that have been tested in recent clinical trials are summarised and advantages and disadvantages of a number of delivery systems and approaches are discussed. Finally, an outlook on how plasmid DNA and viral vectors might be developed further as cancer vaccines is provided.
Anderson
Richard J
RJ
Oxxon Therapeutics Ltd., 2nd Floor Florey House, 3 Robert Robinson Avenue, Oxford Science Park, Oxford OX4 4GP, UK.
Schneider
Joerg
J
D000818:Animals; D019496:Cancer Vaccines / Q000627:therapeutic use*; D016503:Drug Delivery Systems / Q000379:methods*; D005822:Genetic Vectors / Q000276:immunology; D006801:Humans; D009369:Neoplasms / Q000628:therapy*; D010957:Plasmids / Q000235:genetics; D019444:Vaccines, DNA / Q000008:administration & dosage* / Q000276:immunology; D014765:Viral Vaccines / Q000627:therapeutic use*
D019496:Cancer Vaccines; D019444:Vaccines, DNA; D014765:Viral Vaccines